SCHEMBL189451

SCHEMBL189451

N#Cc1c[nH]c(=O)[nH]c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPYD Q12882 4/20 1.00
ALDH1A1 P00352 4/20 0.46
MAPT P10636 2/20 0.46
GAA P10253 1/20 0.46
ATAD2 Q6PL18 1/20 0.46
LMNA P02545 1/20 0.46
CYP19A1 P11511 1/20 0.46
TSHR P16473 1/20 0.46
THPO P40225 1/20 0.46
MTOR P42345 1/20 0.46
HTT P42858 1/20 0.46
HBB P68871 1/20 0.46
PMP22 Q01453 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MCL1 Q07820 4/20 0.42
KDM4E B2RXH2 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HPGD P15428 1/20 0.39
KDM4C Q9H3R0 1/20 0.37
PIK3CD O00329 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Eniluracil SCHEMBL9539455 0.80 DPYD (0.65) DPYDALDH1A1MAPTGAAATAD2
SCHEMBL187437 0.78 DPYD (0.64) DPYDALDH1A1MCL1KDM4ENPSR1
Eniluracil SCHEMBL37817 0.77 DPYD (1.00) DPYDALDH1A1MAPTGAAATAD2
SCHEMBL5045201 0.75 DPYD (0.60) DPYDALDH1A1GAAATAD2MCL1
SCHEMBL30753833 0.75 DPYD (0.59) DPYDALDH1A1GAALMNAMCL1
SCHEMBL1051435 0.74 DPYD (0.59) DPYDALDH1A1MAPTGAAATAD2
SCHEMBL13296 0.74 DPYD (0.59) DPYDALDH1A1MAPTGAAATAD2
SCHEMBL14177211 0.74 DPYD (0.59) DPYDALDH1A1MAPTGAAATAD2
SCHEMBL28592458 0.72 DPYD (0.57) DPYDALDH1A1MAPTGAAATAD2
SCHEMBL5820610 0.71 DPYD (0.55) DPYDALDH1A1MAPTGAAATAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114891041-A Ruthenium arene complex with multiple activities and preparation method and application thereof 重庆医科大学 2022-08-12 CN claimed
CN-108358854-A A kind of preparation method of pharmaceutical intermediate 5- cyanouracils 重庆奥舍生物化工有限公司 2018-08-03 CN claimed
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2017-06-22 US claimed
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Modema Therapeutics, Inc. (US) 2017-05-18 US claimed
EP-3157572-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2017-04-26 EP claimed
EP-3157573-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2017-04-26 EP claimed
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2016-10-20 US claimed
EP-3080289-A2 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2016-10-19 EP claimed
WO-2015196128-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2015-12-23 WO claimed
WO-2015196130-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2015-12-23 WO claimed
WO-2009100367-A2 COMPOSITIONS COMPRISING TOPICAL DPD INHIBITORS AND METHODS OF USING SAME IN THE TREATMENT OF HAND-FOOT SYNDROME ADHEREX TECHNOLOGIES INC. (CA) 2009-08-13 WO claimed
US-20090196833-A1 COMPOSITIONS COMPRISING TOPICAL DPD INHIBITORS AND METHODS OF USING SAME IN THE TREATMENT OF HAND-FOOT SYNDROME ADHEREX TECHNOLOGIES INC. (CA) 2009-08-06 US claimed
US-20080255168-A1 METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS ADHEREX TECHNOLOGIES, INC. (CA) 2008-10-16 US claimed
CN-101068549-A Methods of administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs ADHEREX TECHNOLOGIES INC (CA) 2007-11-07 CN claimed
EP-1827443-A1 METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS Adherex Technologies, Inc. (CA) 2007-09-05 EP claimed
WO-2006060697-A9 METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS ADHEREX TECHNOLOGIES INC (CA) 2006-09-21 WO claimed
US-20060148753-A1 Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs ADHEREX TECHNOLOGIES, INC. (CA) 2006-07-06 US claimed
WO-2006060697-A1 METHODS FOR ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS ADHEREX TECHNOLOGIES, INC. (CA) 2006-06-08 WO claimed
EP-0726904-A1 5-FLUOROURACIL DERIVATIVES THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-21 EP claimed
WO-1995012606-A1 5-FLUOROURACIL DERIVATIVES THE WELLCOME FOUNDATION LIMITED (GB) 1995-05-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 DPYD 250/4885ALDH1A1 1969/4885MAPT 3517/4885
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 DPYD 369/4885ALDH1A1 2324/4885MAPT 3589/4885
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 DPYD 369/4885ALDH1A1 2324/4885MAPT 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.